The humanized anti-interleukin (IL)-6 monoclonal antibody (MAb) clazakizumab passed muster in its first major study, a dose-ranging Phase IIb in 418 adults with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).